Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Intranasal CT001 in Healthy Volunteers
NCT04807335Phase 1Completed
- Sponsor
- Cessatech
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sufentanil and ketamine in acute pain (3 arms), sponsored by Cessatech. Primary endpoints: concentration of CT001 in the blood and Total amount of CT001 in the blood over time. Started Mar 2021; status: completed.
02
Drugs
sufentanilketamine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT04807335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807335.